1 completed, 1 terminated, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow PL-3994: new trials by email Literature Review of PL-3994 trials Research Report on PL-3994
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994 Aqueous Intravenous Solution Single Dose - Heart Failure With Preserved Ejection Fraction | Phase 2 | Terminated | Palatin Technologies, Inc | 15 | 2020-11-12 | 2025-12-15 |
| Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension PL3994, Placebo - Hypertension | Phase 2 | Completed | Palatin Technologies, Inc | 21 | 2008-04-01 | 2013-07-19 |
| Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma PL-3994 - Asthma | Phase 2 | Withdrawn | Palatin Technologies, Inc | 2014-12-16 |
Asthma (1) · Heart Failure (1) · Hypertension (1)
United States (2)
Robert Jordan (1) · Sangiv J. Shah, MD (1) · Steven Fischkoff, MD (1)